Associated Papers
Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y et al.
Scientific Reports, 2024
38238401 (PubMed )
Supplement: 41598_2024_52006_MOESM1_ESM.xlsx › Supplementary_Table_all_list
The Discordance of Gene Mutations between Circulating Tumor Cells and Primary/Metastatic Tumor.
Wang Q et al.
Molecular Therapy Oncolytics, 2019
31650022 (PubMed )
Supplement: mmc3.xls › Sheet1
Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.
Kuiper JL et al.
British Journal of Cancer, 2016
Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma.
Kim EY et al.
Bmc Cancer, 2016
26782967 (PubMed )
Supplement: 12885_2016_2049_MOESM1_ESM.xlsx › Sheet1
Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.
Kim EY et al.
Cancer Biology & Therapy, 2016
Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer.
Cushman-Vokoun AM et al.
American Journal of Clinical Pathology, 2013
Select a paper to view details